论文部分内容阅读
The distinguishing feature and current technique progress of tumor treatment with heavy-ion beams is introduced in the paper. Additional superiority to tumor treatment from a radioactive ion beam (RIB) is emphatically discussed. The experimental research of the radioactive 9C-ion beams aimed at tumor treatment at Heavy Ion Medical Accelerator in Chiba (HIMAC), National Institute of Radiological Sciences (NIRS), Japan is described in detail, including production of the beams, optimization of parameters,distribution of depth dose, survival effect of cell and com parison of RBE between 9C- and 12C-beams. Results show that under 40 mm thick Beryllium target and 10 mm thick aluminum degrader at full (5%) momentum acceptance, the production rate and purity of the produced 9C-beams are 9.07×10-6 and 82.88% respectively with the primary 12Cbeams of 430 MeV/u and 1.8×109 pps. A uniform irradiation field with homogeneity up to 89.6% inside central area 10 mm in diameter is obtained by using spot scanning. In this case, the dose rate at the entrance is 0.5 Gy/h. In survival experiment of cells, the average relative biological effectiveness (RBE) of 9C-beams is 5.28 and 2.93 for 12C-beams in the region around Bragg peak. The RBE of 9C-beams is 1.8 times higher than that of 12C-beams. It indicates that cell-killing efficiency of 9C-beams is stronger than that of 12C-beams.9C-beams are more efficacious for tumor treatment than 12C-beams.